AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06739395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib tablet
Description: Usage, dosage, and administration method: The recommended dose is 2 mg, taken orally once a day with an interval of approximately 24 hours. The dose should be taken at least 1 hour before meals or 2 hours after meals. Do not take any missed doses of trametinib within 12 hours of taking the next dose.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
Study NCT06121505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: Patients will receive sintilimab combined with standard platinum-based doublet chemotherapy for a total of 4 cycles. Patients subsequently received maintenance treatment with sintilimab, and continued treatment until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor treatments, death, or other circumstances that should stop treatment as specified in the protocol. Whichever occurs first. The maximum treatment time with sintilimab is 24 months (or 35 cycles).
Study NCT05667649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RB-ADSC
Description: Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (ADSCs)
Study NCT06121505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: Patients will receive sintilimab combined with standard platinum-based doublet chemotherapy for a total of 4 cycles. Patients subsequently received maintenance treatment with sintilimab, and continued treatment until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor treatments, death, or other circumstances that should stop treatment as specified in the protocol. Whichever occurs first. The maximum treatment time with sintilimab is 24 months (or 35 cycles).
Study NCT06121505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Patients will receive sintilimab combined with standard platinum-based doublet chemotherapy for a total of 4 cycles. Patients subsequently received maintenance treatment with sintilimab, and continued treatment until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor treatments, death, or other circumstances that should stop treatment as specified in the protocol. Whichever occurs first. The maximum treatment time with sintilimab is 24 months (or 35 cycles).
Study NCT06121505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab
Description: Patients will receive sintilimab combined with standard platinum-based doublet chemotherapy for a total of 4 cycles. Patients subsequently received maintenance treatment with sintilimab, and continued treatment until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor treatments, death, or other circumstances that should stop treatment as specified in the protocol. Whichever occurs first. The maximum treatment time with sintilimab is 24 months (or 35 cycles).
Study NCT05015114 — intervention group
Intervention type: OTHER
Intervention: Sarcopenia Assessment
Description: Sarcopenia Assessment
Study NCT06037954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Patient demographic characteristics, Clinical variables, Cornell Service Index-Short Form (CSI), Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder scale-7 (GAD-7), Client Satisfaction Questionnaire (CSQ-8), Intention to Seek Help Scale, Health Beliefs about Mental Illness Instrument (HBMII) - Emotional/Nervous Severity Scale, Health Beliefs about Mental Illness Instrument (HBMII) - Emotional/Nervous Benefits Scale, Barriers to Mental Health Services Scale-Revised, Cues to action, Self-Efficacy to Seek Mental Health Care (SE-SMHC)
Study NCT06037954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interviews
Description: Interviews will be conducted by the qualitative methods specialist and trained study staff and will last 30-45 minutes.
Study NCT06037954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30-minute telephone or videoconference sessions
Description: Includes five components delivered in three 30-minute telephone or videoconference visits over six weeks and one booster telephone call. All sessions are audio-recorded. The five components are:~1. Provide education about depression and treatment options~2. Identify treatment preferences and a personal goal achievable with mental health care~3. Assess barriers to treatment initiation~4. Recommend a referral using standardized referral options~5. Address barriers to accessing care
Study NCT05330377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib 40 MG Oral Tablet
Description: Gilteritinib is an oral FLT3 inhibitor, and is active against both FLT3-ITD and FLT3-TKD mutations. Gilteritinib will be given orally according to the assigned phase I dose cohort starting day 6 until day 19. Participants will be given the daily dose with water as at the same time each morning. Gilteritinib should be taken at least 2 hours after or 1 hour before consuming food.
Study NCT05330377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Cladribine is given intravenously at a dose of 5 mg/m2 I.V. over 2 hours once per day on days 1 to 5.
Study NCT05330377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine is given intravenously at a dose of 2,000 mg/m2 I.V. over 4 hours once per day on days 1 to 5, given second, 2 hours after cladribine.
Study NCT05330377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim (GCSF) or biosimilar, will be given at a dose of 300 mcg S.C. once per day on days 0 to 5, started 24 hours prior to chemotherapy. If WBC is > 20 × 109/L on day 0, the filgrastim dose on day 0 will be omitted.
Study NCT05330377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Mitoxantrone is given intravenously at a dose of 10 mg/m2 I.V. over 2 hours once per day on days 1 to 3.
Study NCT06061159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: initial dose is 0.2mg/kg；adjust dosage is 0.05mg/kg
Study NCT04935619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Reinforcement
Description: Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.
Study NCT04935619 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Non-Contingency Reinforcement
Description: Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.
Study NCT05563974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family led postnatal care
Description: Family-led Postnatal Care-FPNC A midwife involves families and uses a visual checklist to assess and counsel. The midwife then gives families the checklist and guides them how to retrieve a home care kit that has a blood pressure machine, infrared thermometer, and health education booklet.~At home, families assess the health of postnatal mothers and newborns for 6 days, and then return the completed checklist and home care kit to the community location.
Study NCT06460909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological support
Description: An interview with the psychologist before surgery.
Study NCT05290298 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NITRATE
Description: Multi-component nutritional formula
Study NCT05290298 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo
Study NCT06015945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Acustimulation (TEA)
Description: The severity and frequency participants pain will be measured during a run-in period of 2 weeks with to assess baseline pain severity and frequency. Eligible participants will have a 4-week treatment period at home. Stimulation with the TEA device will be performed for 30 minutes twice per day, in the morning and in the evening.~In addition to using the device, participants will have study visits, complete surveys, as well as provide medical information during the study.
Study NCT04987229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLZ/SAM
Description: Olanzapine and Samidorphan fixed dose coated tablet taken once daily
Study NCT05480696 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharide enriched inulin supplement
Description: Experiment
Study NCT05480696 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Maltodextrin
Description: Placebo.
Study NCT06638879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Participants will receive a tacrolimus treatment via toothpaste application twice daily for three months.
Study NCT05633667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab (ZIM)
Description: Administered intravenously
Study NCT05633667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zimberelimab (ZIM)
Description: Administered intravenously
Study NCT05633667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab (DOM)
Description: Administered intravenously
Study NCT05633667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan-hziy (SG)
Description: Administered intravenously
Study NCT05633667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacituzumab govitecan-hziy (SG)
Description: Administered intravenously
Study NCT05633667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant (ETRUMA)
Description: Administered orally
Study NCT05633667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered intravenously
Study NCT05633667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously
Study NCT05633667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered intravenously
Study NCT05633667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Administered intravenously
Study NCT05633667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered intravenously
Study NCT05633667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered intravenously
Study NCT05633667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered intravenously
Study NCT06739395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Usage and dosage: Take 150mg orally twice a day, with an interval of about 12 hours.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided. When this product is used in combination with trametinib, it should be taken once a day at the same time, along with this product administered in the morning or evening.The dosage for combined use will be adaptively adjusted by the researcher.
Study NCT06739395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vebreltinib Enteric Capsules
Description: Usage and dosage: The recommended starting dose is 200 mg/time, taken orally twice a day (once in the morning and once in the evening), until disease progression or intolerable toxicity occurs.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
Study NCT06739395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib Pill
Description: Usage and dosage: The recommended dosage is 300mg (two 150mg film tablets), taken once a day with food; Continue treatment until the disease worsens or unacceptable toxicity occurs.Administration method: Patients should take aspirin at approximately the same time every day and swallow the entire aspirin tablet (the tablet should not be chewed, crushed, or separated before swallowing).The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
Study NCT06739395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-Hziy 180 MG
Description: Usage and dosage: The recommended dosage is 10 mg/kg, administered intravenously every 21 days as a treatment cycle on the 1st and 8th days, and continued until disease progression or unacceptable toxicity occurs. The dosage of this product should not exceed 10 mg/kg.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
Study NCT06003959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine nursing care
Description: Preterm infants in the control group did not receive any intervention other than the routine feeding protocol applied in the clinic.
Study NCT06003959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breastfeeding support system
Description: The body weight of preterm infants in the experimental group was measured and recorded each morning before their first feeding. Mothers of these infants were asked to complete the Mother-Infant Attachment Scale (MIAS) prior to the procedure. The physician determined the appropriate amount of breast milk the infant should receive during feeding. Before each feeding, the neonatal nurse ensured the sterile preparation of the milk and transferred it to the Breastfeeding Support System. The mothers were then prepared for the procedure, with the neonatal nurse explaining how the breastfeeding support system worked. Once both the mother and baby were ready, the baby was placed at the mother's breast. After feeding, the mothers were asked to complete the MIAS again.
Study NCT06061445 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with TKI and Anti-PD-1 Antibody
Description: After signing informed consent, patients received Anti-PD-1 Antibody 200 mg intravenously on the first day of each cycle, Q3W; Tyrosine Kinase Inhibitor (TKI) was administration started on the first and continually administered until disease progression developed or serious treatment-related toxicity occurred; Cancer thrombus radiotherapy treatment: For the portal vein cancer thrombus site (Total dose 25-30Gy, times 5-6) , Treatment usually starts within 7 days and ends within 1 week after the first cycle of injection of anti PD-1 inhibitors.
Study NCT04558502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline hydrochloride capsule
Description: Antibiotic for H. pylori eradication
Study NCT04558502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Antibiotic for H. pylori eradication
Study NCT04558502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication
Study NCT04558502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication
Study NCT04558502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colloidal bismuth pectin
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study NCT04558502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colloidal bismuth pectin
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study NCT04558502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Description: Proton pump inhibitor
Study NCT04558502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: Proton pump inhibitor
Study NCT06427447 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy
Description: Upfront chemotherapy (gemcitabine plus capecitabine) followed chemoradiotherapy (radiotherapy with concurrent capecitabine)
Study NCT06427447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy
Description: Chemotherapy (gemcitabine plus capecitabine)
Study NCT06559982 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brown seaweed and tart cherry blend
Description: Blend of brown seaweed and tart cherry blend taken twice daily
Study NCT06559982 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical in taste and colour to the supplement, but with no brown seaweed or tart cherry.
Study NCT06356766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Modified Duran Protocol via Telerehabilitation
Study NCT06356766 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face rehabilitation
Description: Modified Duran Protocol
Study NCT05633667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Administered intravenously
Study NCT05633667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Administered intravenously
Study NCT05633667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Administered intravenously
Study NCT04658069 — intervention group
Intervention type: OTHER
Intervention: no specific interventions
Description: no specific interventions
Study NCT05647993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Injection [Zithromax]
Description: Intervention group patient will receive standard antimicrobial prophylaxis(cefazolin intravenously weight dependent) and azithromycin 500 mg intravenously before the incision
Study NCT05647993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cefazolin
Description: All the participants will receive the cefazolin intravenously. The dosage of the cefazolin is depend on participant's weight. The participant with weight less than 80kg will receive cefazolin 1 gm and between 80-120kg will receive cefazolin 2 gm and for the participant with more than 120kg will receive cefazolin 3 gm before the incision.
Study NCT05647993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: All the participants will receive the cefazolin intravenously. The dosage of the cefazolin is depend on participant's weight. The participant with weight less than 80kg will receive cefazolin 1 gm and between 80-120kg will receive cefazolin 2 gm and for the participant with more than 120kg will receive cefazolin 3 gm before the incision.
Study NCT05647993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Intravenous Solution
Description: For the placebo group will receive the cefazolin intravenously and 0.9% NaCl 100ml before the incision
Study NCT01089192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT01089192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT04728945 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lung recruitment
Description: Automatic lung recruitment using the anesthetic machines (with PEEP 15 cmH2O for 30 seconds) will be performed every 30 minutes during laparoscopy.
Study NCT04728945 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard ventilatory management
Description: After tracheal intubation, standard ventilatory management (metered ventilation) should be performed with the following initial settings, and rescue should be performed when hypoxemia occurs, if necessary.~\[initial setting\] PEEP 4cmH2O, FIO2 0.3 Ventilation rate: 6-8 ml/kg predicted body weight (PBW)
Study NCT04728945 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard ventilatory management
Description: After tracheal intubation, standard ventilatory management (metered ventilation) should be performed with the following initial settings, and rescue should be performed when hypoxemia occurs, if necessary.~\[initial setting\] PEEP 4cmH2O, FIO2 0.3 Ventilation rate: 6-8 ml/kg predicted body weight (PBW)
Study NCT04428658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supplemental video visits
Description: Receiving home-based video visits with a pediatric endocrinologist monthly as a supplement to regular diabetes clinic visits.